Please assess the completion status of the following clinical trial:

Trial Title: Trauma Acute Pain Treatment With Methoxyflurane Vaporized (PENTHROX®): Efficacy and Safety Study (MEDITA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be provided by each patient prior to any study-specific activity. In cases where the patient is unable to write autonomously, it must be obtained a verbal consent in presence of a witness that the patient will have to confirm autonomously as soon as (s)he is able~* Stable, vigilant and collaborative patient i.e. able to understand and communicate with the examiner in order to carry out the study activities~* Age ≥ 18 years~* Trauma to the limbs (fracture, dislocation, crushing, bruising) in a single district.~N.B. For recruiting, given the particular setting, no instrumental confirmation is required but suspicion of involvement of a single district is sufficient.~- Moderate to severe pain, detected by the Numerical Rating Scale (NRS score ≥4)~Exclusion Criteria:~* Personal or family history (parents or siblings) for malignant hyperthermia.~* History of severe adverse reactions to inhaled anesthetics.~* History of renal failure~* History of liver failure.~* Trauma risky dynamics (ejection from the vehicle, cabin deformation, death of an occupant of the same vehicle, motor vehicle / pedestrian or cyclist impact with a motor vehicle in motion, projection / overturn, fall from a height of\> 3 meters, extraction on event place \> 20 min).~* Altered level of vigilance and / or conscience (GCS \<15)~* Symptomatic hypotension or Systolic Pressure \<100 mm / Hg~* Discomfort with Respiratory Rate \> 20 and Oxygen Saturation \<95%~* Known pregnancy status.Note: a 1 day delay with respect to the planned menstruation date (28days since the beginning of the previous one) has to be considered a suspected pregnancy.~* Hypersensitivity to methoxyflurane, to any fluorinated anesthetic or to the E321 butylhydroxytoluene excipient.~* Current treatment with any analgesic for chronic pain or in the previous 5 hours (8 hours in the case of diclofenac).~* Known allergy to both paracetamol and non-steroidal anti-inflammatory drugs or known hypersensitivity to morphine~* All types of acute abdomen and paralytic ileus~* Hearth failure~* Recent (within2 months) biliary tract surgery~* Current bronchial asthma attack~* Uncontrolled epilepsy~* Depressive state treated with Monoamine Oxidase Inhibitors (ongoing or interrupted less 3 wks ago)~* Treatment with naltrexone~* History of active or recurrent peptic ulcer/hemorrhage (2 or more episodes of documented ulceration or bleeding in the last 6 months)~* Bleeding diathesis~* Current Intensive diuretic therapy~* Chronic dyspepsia, gastritis with significant episodes in the last 2 months~* Leucopenia and thrombocytopenia, current hemorrhages~* Current anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A_test drug_Methoxyflurane (Penthrox®) (Type: EXPERIMENTAL): Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
- B_comparator_Morphine/Paracetamol/Ketoprofen (Type: ACTIVE_COMPARATOR): The comparator to be administered will vary according to pain intensity and local clinical practice.~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .~Maximum time of infusion 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).